

# Trial : NL83392.078.23

Published: 13-02-2023

Last updated: 07-12-2024

Publication withdrawn by sponsor

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Other
<b>Health condition type</b>	Reproductive neoplasms female malignant and unspecified
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON53922

### Source

ToetsingOnline

### Brief title

NL83392.078.23

### Condition

- Reproductive neoplasms female malignant and unspecified

### Synonym

Recurrent Ovarian Cancer / Ovarian Cancer

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Regeneron Pharmaceuticals, Inc.

**Source(s) of monetary or material Support:** Industry

### Intervention

**Keyword:** Open-label, Ovarian Cancer

## Outcome measures

### Primary outcome

Publication withdrawn by sponsor

### Secondary outcome

Publication withdrawn by sponsor

## Study description

### Background summary

Publication withdrawn by sponsor

### Study objective

Publication withdrawn by sponsor

### Study design

Publication withdrawn by sponsor

### Intervention

Publication withdrawn by sponsor

### Study burden and risks

Publication withdrawn by sponsor

## Contacts

### Public

Regeneron Pharmaceuticals, Inc.

US

### Scientific

Regeneron Pharmaceuticals, Inc.

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Publication withdrawn by sponsor

### Exclusion criteria

Publication withdrawn by sponsor

## Study design

### Design

Study phase:	2
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

### Recruitment

NL	
Recruitment status:	Other
Start date (anticipated):	22-04-2024

Enrollment: 21  
Type: Actual

## Medical products/devices used

Registration: No

## Ethics review

Approved WMO  
Date: 13-02-2023  
Application type: First submission  
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO  
Date: 10-07-2023  
Application type: First submission  
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO  
Date: 08-01-2024  
Application type: Amendment  
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO  
Date: 04-03-2024  
Application type: Amendment  
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

**Other (possibly less up-to-date) registrations in this register**

No registrations found.

**In other registers**

<b>Register</b>	<b>ID</b>
EU-CTR	CTIS2024-510783-23-00
EudraCT	EUCTR2019-003298-24-NL
ClinicalTrials.gov	NCT03564340
CCMO	NL83392.078.23